AssetMark Inc’s Teva Pharmaceuticals TEVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.75M | Buy |
81,250
+17,936
| +28% | +$597K | ﹤0.01% | 880 |
|
|
2026
Q1 | $1.91M | Buy |
63,314
+7,694
| +14% | +$248K | ﹤0.01% | 899 |
|
|
2025
Q4 | $1.74M | Buy |
55,620
+18,566
| +50% | +$457K | ﹤0.01% | 887 |
|
|
2025
Q3 | $748K | Buy |
37,054
+16,979
| +85% | +$298K | ﹤0.01% | 1023 |
|
|
2025
Q2 | $336K | Buy |
20,075
+11,613
| +137% | +$187K | ﹤0.01% | 1112 |
|
|
2025
Q1 | $130K | Buy |
8,462
+3,257
| +63% | +$58.2K | ﹤0.01% | 1228 |
|
|
2024
Q4 | $115K | Buy |
5,205
+4,851
| +1,370% | +$88.3K | ﹤0.01% | 1215 |
|
|
2024
Q3 | $6.38K | Sell |
354
-192
| -35% | -$3.36K | ﹤0.01% | 1703 |
|
|
2024
Q2 | $8.87K | Buy |
+546
| New | +$8.41K | ﹤0.01% | 1518 |
|
|
2019
Q3 | – | Sell |
-1,512
| Closed | -$14K | – | 1419 |
|
|
2019
Q2 | $14K | Sell |
1,512
-36
| -2% | -$434 | ﹤0.01% | 939 |
|
|
2019
Q1 | $24K | Sell |
1,548
-100
| -6% | -$1.76K | ﹤0.01% | 845 |
|
|
2018
Q4 | $25K | Sell |
1,648
-800
| -33% | -$16.4K | ﹤0.01% | 839 |
|
|
2018
Q3 | $53K | Sell |
2,448
-120
| -5% | -$2.79K | ﹤0.01% | 730 |
|
|
2018
Q2 | $62K | Buy |
2,568
+954
| +59% | +$19.5K | ﹤0.01% | 676 |
|
|
2018
Q1 | $28K | Sell |
1,614
-297
| -16% | -$5.8K | ﹤0.01% | 884 |
|
|
2017
Q4 | $36K | Sell |
1,911
-64
| -3% | -$963 | ﹤0.01% | 862 |
|
|
2017
Q3 | $35K | Sell |
1,975
-999
| -34% | -$22.5K | ﹤0.01% | 786 |
|
|
2017
Q2 | $99K | Buy |
2,974
+1,020
| +52% | +$31.6K | ﹤0.01% | 554 |
|
|
2017
Q1 | $63K | Sell |
1,954
-2,173
| -53% | -$74.2K | ﹤0.01% | 593 |
|
|
2016
Q4 | $150K | Sell |
4,127
-1,072
| -21% | -$42.8K | ﹤0.01% | 443 |
|
|
2016
Q3 | $239K | Sell |
5,199
-595
| -10% | -$31K | ﹤0.01% | 374 |
|
|
2016
Q2 | $291K | Buy |
5,794
+719
| +14% | +$38.3K | ﹤0.01% | 353 |
|
|
2016
Q1 | $272K | Sell |
5,075
-26,669
| -84% | -$1.56M | ﹤0.01% | 343 |
|
|
2015
Q4 | $2.08M | Buy |
31,744
+14,403
| +83% | +$890K | 0.04% | 210 |
|
|
2015
Q3 | $979K | Sell |
17,341
-28,209
| -62% | -$1.83M | 0.02% | 238 |
|
|
2015
Q2 | $2.69M | Sell |
45,550
-2,424
| -5% | -$150K | 0.06% | 151 |
|
|
2015
Q1 | $2.99M | Sell |
47,974
-2,213
| -4% | -$129K | 0.06% | 130 |
|
|
2014
Q4 | $2.89M | Buy |
50,187
+16,705
| +50% | +$931K | 0.06% | 146 |
|
|
2014
Q3 | $1.8M | Sell |
33,482
-1,610
| -5% | -$85.3K | 0.04% | 220 |
|
|
2014
Q2 | $1.84M | Sell |
35,092
-4,333
| -11% | -$221K | 0.04% | 218 |
|
|
2014
Q1 | $2.08M | Sell |
39,425
-1,885
| -5% | -$87.1K | 0.05% | 152 |
|
|
2013
Q4 | $1.66M | Sell |
41,310
-4,167
| -9% | -$164K | 0.04% | 196 |
|
|
2013
Q3 | $1.72M | Buy |
+45,477
| New | +$1.77M | 0.04% | 193 |
|
Other funds holding TEVA
HIIFS
PF
CI
MMH
MIFH
LIM
AssetMark Inc's TEVA Position: Q2 2026 in Review
AssetMark Inc increased its Teva Pharmaceuticals (TEVA) stake by 28% in Q2 2026, buying an estimated $597K and bringing the position to 81,250 shares worth $2.75M. The position accounts for ﹤0.01% of the portfolio, ranked #880.
AssetMark Inc first reported a position in TEVA in Q3 2013 and has held it in 33 quarters since. The position peaked at $2.99M in Q1 2015. 672 funds tracked by Wall St. Rank hold TEVA as of Q2 2026.
- AssetMark Inc held 81,250 shares of Teva Pharmaceuticals worth $2.75M as of Q2 2026.
- AssetMark Inc bought 17,936 Teva Pharmaceuticals shares in Q2 2026, an estimated $597K.
- Teva Pharmaceuticals made up ﹤0.01% of AssetMark Inc's portfolio in Q2 2026, its #880 holding.
- AssetMark Inc first reported a position in Teva Pharmaceuticals in Q3 2013 and has held it in 33 quarters since.
- AssetMark Inc's Teva Pharmaceuticals position peaked at $2.99M in Q1 2015.
- 672 funds tracked by Wall St. Rank held Teva Pharmaceuticals as of Q2 2026.
Based on AssetMark Inc's 13F filing for Q2 2026, filed 30 Jul 2026.